PHS: PH:FB
Quotes are delayed by 20 min
Mar 28, 2023, 2:52 p.m.
₱
47.00
Change
-1.00 -2.08%
Volume
Volume 60,400
Quotes are delayed by 20 min
Previous close
₱ 48.00
₱ 47.00
Change
-1.00 -2.08%
Day low
Day high
₱46.60
₱48.25
52 week low
52 week high
₱34.10
₱63.80
Mr. Ramon S. Ang Vice Chairman, President & Chief Executive Officer |
Mr. Iidefonso B. Alindogan Vice President, Chief Financial & Strategy Officer |
Mr. Francisco S. Alejo Director & Chief Operating Officer-Food |
Ms. Alexandra Bengson-Trillana Secretary, General Counsel & Compliance Officer |
Mr. Oscar R. Sañez Vice President & Group Head-Corporate Affairs |
Mr. Roberto N. Huang Director & Chief Operating Officer-Beer |
Dr. Emmanuel B. Macalalag Director & Chief Operating Officer-Spirits |
Ms. Romela M. Bengzon Non-Executive Director |
Mr. Francis H. Jardeleza Director |
Mr. John Paul L. Ang Non-Executive Director |
Mr. Menardo R. Jimenez Non-Executive Director |
Mr. Ferdinand K. Constantino Treasurer & Director |
Ms. Aurora T. Calderon Non-Executive Director |
Mr. Johanna Dominique G. Esteban Head-Internal Audit |
Ms. Kristina Lowella Garcia Assistant VP & Manager-Investor Relations |
Ms. Aurora S. Lagman Independent Director |
Mr. Ricardo C. Marquez Independent Non-Executive Director |
Mr. Cirilo P. Noel Independent Director |
Mr. Winston A. Chan Independent Director |
Walgreens Q2 adj. EPS down 27% from a year ago to $1.16, but above the FactSet consensus $1.10
Why I abandoned my 529 college savings plan and switched to Series I bonds instead
Disney Drops Metaverse Hopes. The 'Next Storytelling Frontier' Is Out of Favor.
The Metaverse Suffers a Setback. That’s OK, Banking Regulation Needs to Catch Up.
Bowlero started at buy with $26 stock price target at Stifel Nicolaus
Alibaba stock up 6.6% in premarket trade on plan to form six units
CytomX Therapeutics stock price target cut to $2 from $4 at Mizuho
Unity Biotechnology stock price target cut to $6 from $12 at Mizuho
Marathon Petroleum downgraded to neutral from overweight at J.P. Morgan
BREAKING
McCormick & Co. Q1 adj. earnings 59c beats analyst view of 50c
McCormick & Co. Q1 revenue up 3% to $1.57 bln, ahead of $1.54 bln analyst estimate
McCormick sees FY2023 adj. EPS $2.56-$2.61, surrounds FactSet consensus $2.57
McCormick Q1 sales rose 3% to $1.57 bln, above the FactSet consensus $1.55 bln
Virtual Stock Exchange